Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone.
Level 5 - mechanism / opinion, no new human data
Non-clinical bench and animal study
PubMed 32905811 · doi:10.1016/j.bbr.2020.112896
What was done
Researchers tested whether the non-opioid enantiomer (+)-naltrexone ((+)-NTX), identified as a dual TLR2/TLR4 antagonist, could prevent learning and memory disturbances and neuroinflammation in two rat strains. A low-dose experimental autoimmune encephalomyelitis (EAE) model was used to induce MS-like pathology without motor impairments. Fourteen days post-induction, rats received daily subcutaneous injections of (+)-NTX or saline. Hippocampal and amygdalar function were evaluated at day 21 using contextual and auditory-fear conditioning. Hippocampal mRNA expression of IL-1β, TLR2, TLR4, NLRP3, and IL-17, along with microglial Iba1 expression in CA1 and dentate gyrus, were analyzed.
What was found
The abstract reports no numerical values or confidence intervals. Low-dose EAE impaired long-term contextual fear memory while sparing short-term contextual memory and auditory-cued fear memory. EAE increased hippocampal mRNA for IL-1β, TLR2, TLR4, NLRP3, and IL-17, and elevated Iba1 expression in CA1 and dentate gyrus. Treatment with (+)-NTX completely prevented the EAE-induced memory impairments and attenuated the hippocampal proinflammatory markers.
Why it matters
Cognitive deficits in multiple sclerosis are difficult to manage and closely linked to neuroinflammation. This study shows that targeting innate immune signaling via dual TLR2/TLR4 blockade can prevent hippocampal-dependent memory deficits in a preclinical model.
Limits
The study is restricted to a rodent model of MS, and the abstract omits sample sizes, exact dosages, and quantitative statistical metrics. In addition, findings from an acute, low-dose EAE model may not fully capture the complexity, chronicity, or diverse manifestations of human MS cognitive impairment.
Cited by
- context Low-dose naltrexone inhibits the NLRP3 inflammasome pathway.